<DOC>
	<DOCNO>NCT00273325</DOCNO>
	<brief_summary>Premature infant high risk pneumonia . The PCV-7 vaccine effectively prevent invasive disease Streptococcus pneumoniae full-term infant , thoroughly studied premature infant . This study evaluate effectiveness safety vaccine give routine practice low birth weight infant , look blood antibody level 4-6 week final vaccine dose , adverse event , survival , infection , neurodevelopmental outcomes 18-22 month correct age .</brief_summary>
	<brief_title>Immunogenicity PCV-7 Vaccine VLBW Infants</brief_title>
	<detailed_description>Streptococcus pneumoniae cause estimate 10-25 % pneumonia United States , responsible estimate 40,000 death per year . Invasive pneumococcal disease peak incidence 235/100,000 among child age 6-11 month . Pneumococcal meningitis carry high risk death ( 15 % ) neurodevelopmental impairment ( 12-28 % ) Hib Neisseria meningitides . Premature infants high risk invasive disease Streptococcus pneumoniae . The heptavalent pneumococcal-CRM197 conjugate vaccine ( PCV-7 ) effectively prevent invasive pneumococcal disease full-term infant , incompletely studied premature infant . The American Academy Pediatrics ( AAP ) recommend `` prematurely born infant , include infant low birth weight , immunize usual chronological age case '' , caution `` study suggest reduce immune response low-birth-weight infant ( &lt; 1500 g ) . '' This observational study assess effectiveness PCV-7 vaccine generate sufficient immune response safe manner give low birth weight ( VLBW ) infant routine pediatric practice . We hypothesize among VLBW infant , frequency estimate minimum protective antibody titer PCV-7 ( &gt; =0.15 Î¼g/mL ) would decrease decrease birth weight . Infants 501-1500g birth weight &lt; 32 0/7 week gestational age enrol nine NICHD Neonatal Research Network center 2004 2006 . Enrollment stratify weight group yield approximately 20 infant per 100g increment 501-1500g birth weight whose primary PCV-7 series initiate 3 month complete 8 month birth . The infant ' primary provider give PCV-7 vaccination 2 , 4 , 6 month birth . Infants single 2-ml blood sample draw 4-6 week follow third dose PCV-7 . Antibodies seven vaccine serotypes include PCV-7 measure enzyme-linked immunosorbent assay . Children follow 18-22 month correct age ass survival , infection , neurodevelopmental outcome .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion Gestational age &lt; 32 0/7 week Included Neonatal Research Network Generic Database Family telephone home Anticipated availability blood draw 46 week follow 3rd vaccine dose Consent obtain first dose PCV7 give Exclusion criterion Known immunodeficiency HIV exposure Parental nonconsent Primary care pediatrician willing participate Enrollment conflict trial Infant receive first dose PCV7 vaccine 3 month age</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>NICHD Neonatal Research Network</keyword>
	<keyword>Very Low Birth Weight ( VLBW )</keyword>
	<keyword>Extremely Low Birth Weight ( ELBW )</keyword>
	<keyword>Prematurity</keyword>
	<keyword>Pneumococcal Vaccines</keyword>
	<keyword>Vaccines , Conjugate</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Vaccine Response</keyword>
	<keyword>Heptavalent pneumococcal conjugate vaccine ( PCV-7 )</keyword>
	<keyword>pneumococcal polysaccharide , type 6B</keyword>
	<keyword>Pneumococcal polysaccharide , type 14</keyword>
	<keyword>Pneumococcal polysaccharide , type 19F ,</keyword>
	<keyword>Pneumococcal polysaccharide , 23F</keyword>
	<keyword>Pneumococcal polysaccharide , 18C</keyword>
	<keyword>Pneumococcal polysaccharide , 4</keyword>
	<keyword>Pneumococcal polysaccharide , 9V</keyword>
</DOC>